Anemia of chronic kidney disease: CHOIR and the FDA
- 26 June 2007
- journal article
- research article
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 3 (8) , 406-407
- https://doi.org/10.1038/ncpneph0539
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysisThe Lancet, 2007
- Haemoglobin targets: we were wrong, time to move onThe Lancet, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIRNephrology Dialysis Transplantation, 2006
- Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis PatientsJournal of the American Society of Nephrology, 2006
- Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney diseaseAmerican Heart Journal, 2005
- Death, Hospitalization, and Economic Associations among Incident Hemodialysis Patients with Hematocrit Values of 36 to 39%Journal of the American Society of Nephrology, 2001
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998